Voyager goes big, securing multi-billion dollar gene therapy development deal with Neurocrine

Paul Schloesser

Associate Editor

The neurological disease outfit helmed by Biogen’s former R&D chief announced a big gene therapy deal Monday, starting #JPM23 with its largest deal to date …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Voyager goes big, securing multi-billion dollar gene therapy development deal with Neurocrine

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Voy­ager goes big, se­cur­ing mul­ti-bil­lion dol­lar gene ther­a­py de­vel­op­ment deal with Neu­ro­crine

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Voyager goes big, securing multi-billion dollar gene therapy development deal with Neurocrine